Results 101 to 110 of about 7,383 (189)

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. [PDF]

open access: yesNat Med, 2023
Subbiah V   +22 more
europepmc   +1 more source

First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer. [PDF]

open access: yesClin Cancer Res
Yap TA   +16 more
europepmc   +1 more source

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. [PDF]

open access: yesOncologist
Boisteau E   +25 more
europepmc   +1 more source

First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA). [PDF]

open access: yesCancers (Basel)
Legoux JL   +16 more
europepmc   +1 more source

A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. [PDF]

open access: yesERJ Open Res, 2020
Legoupil C   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy